Skyrizi — Competitive Intelligence Brief

Skyrizi (RISANKIZUMAB) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-23 Antagonist [EPC]. Area: Immunology.

marketed Interleukin-23 Antagonist [EPC] Interleukin-23 subunit alpha Immunology Monoclonal antibody

Target snapshot

Skyrizi (RISANKIZUMAB) — AbbVie. Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Skyrizi TARGET	RISANKIZUMAB	AbbVie	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Omvoh	MIRIKIZUMAB	Eli Lilly Nederland B.V.	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2023-01-01
OMVOH	MIRIKIZUMAB-MRKZ	ELI LILLY AND CO	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha
Sunpg 1622	TILDRAKIZUMAB	Sun Pharma Global	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23	2018-01-01
Tremfya	GUSELKUMAB	Johnson & Johnson	marketed	Interleukin-23 Antagonist [EPC]	p19 subunit of IL-23	2017-01-01
ILUMYA	TILDRAKIZUMAB-ASMN	SUN PHARMA GLOBAL	marketed	Interleukin-23 Antagonist [EPC]	Interleukin-23

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-23 Antagonist [EPC] class)

1. AbbVie · 1 drug in this class
2. ELI LILLY AND CO · 1 drug in this class
3. Eli Lilly Nederland B.V. · 1 drug in this class
4. Johnson & Johnson · 1 drug in this class
5. SUN PHARMA GLOBAL · 1 drug in this class
6. Sun Pharma Global · 1 drug in this class